Immune Parameters in The Prognosis and Therapy Monitoring of Cutaneous Melanoma Patients: Experience, Role, and Limitations

Figure 2

Peripheral blood lymphocytes in cutaneous melanoma patients in comparison to normal ranges (% from CD45+ pan leukocytic antigen)—CD8+ in stages I and II compared to normal values 𝑃<0.005, CD19+ in stages III and IV compared to normal values 𝑃<0.005.